Charles River Laboratories (CRL): Laboratories to acquire

Charles River Laboratories (CRL) said it agreed to acquire Frontage Holdings' bioanalysis and DMPK operations in Exton, Pennsylvania, for about $470 million in cash plus up to $75 million in performance-based contingent payments. The deal, disclosed in a November 9, 2026 Form 8-K, includes a CLIA-certified central laboratory and two sites totaling roughly 150,000 square feet with about 340 employees. CEO Birgit Girshick said the purchase accelerates the company's strategy to expand clinical bioanalysis and DMPK capabilities as biologics and complex modalities grow in development pipelines. The transaction is expected to close in the first half of 2027, pending shareholder and regulatory approvals and customary closing conditions. It matters because Charles River is betting the added clinical-stage testing capacity will deepen its preclinical-to-clinical offering and improve long-term growth. Next, investors will watch for approval progress and any updates on how the acquired assets affect CRL's growth outlook.